Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.
Urology case reports. 2016*** epublish ***
Hyun Kim, Mohammed Alshalalfa, Jean Hoffman-Censits, Costas D Lallas, Elai Davicioni, Jianqing Lin, Ruth Birbe, Nicholas Erho, Jonathan Lehrer, Hussam Al-Deen Ashab, Mandeep Takhar, Anders Olson, Lucia L C Lam, W Kevin Kelly, Karen E Knudsen, Chellappagounder Thangavel, Roland Seiler, Felix Y Feng, Edward M Schaeffer, Edouard J Trabulsi, Leonard G Gomella, Mark D Hurwitz, Adam P Dicker, Robert B Den
Sidney Kimmel Cancer Center, Thomas Jefferson University, PA, USA., GenomeDx Biosciences Inc., Vancouver, BC, Canada., GenomeDx Biosciences Inc., Vancouver, BC, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Department of Radiation Oncology, University of California, San Francisco, CA, USA., Department of Urology, Feinberg School of Medicine, Northwestern University, IL, USA.